Lakeshore Capital Group Inc. Makes New $324,000 Investment in Pfizer Inc. (NYSE:PFE)

Lakeshore Capital Group Inc. purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 12,197 shares of the biopharmaceutical company's stock, valued at approximately $324,000.

A number of other institutional investors have also made changes to their positions in the stock. Norges Bank bought a new stake in shares of Pfizer in the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. grew its stake in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Starboard Value LP bought a new stake in shares of Pfizer in the fourth quarter worth about $407,730,000. Raymond James Financial Inc. bought a new position in shares of Pfizer during the 4th quarter valued at about $274,694,000. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock traded up $0.29 during trading on Tuesday, reaching $23.61. 36,119,931 shares of the company's stock were exchanged, compared to its average volume of 41,080,360. The firm's fifty day moving average price is $23.33 and its 200-day moving average price is $25.13. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $134.23 billion, a PE ratio of 16.74, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the business posted $0.82 EPS. The company's revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.29%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.